| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by (used in) financing activities | 1,751 | 1,738 |
| Net increase (decrease) in cash and cash equivalents and restricted cash | -150,247 | -131,302 |
| Cash and cash equivalents at beginning of period | 163,543 | - |
| Cash and cash equivalents at end of period | 13,296 | - |
Protara Therapeutics, Inc. (TARA)
Protara Therapeutics, Inc. (TARA)